Tesaro Inc

Tesaro — Q3 2014 Earnings Presentation

15 slides from Tesaro's earnings presentation, Nov 5, 2014

  1. Slide 1: Third-Quarter 2014 Results

    Third-Quarter 2014 Results November 5, 2014

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,

  3. Slide 3: Lonnie Moulder, Chief Executive Officer

    Lonnie Moulder Chief Executive Officer

  4. Slide 4: A Balanced Portfolio of Product Candidates

    4 CINV: Chemotherapy-induced nausea & vomiting A/C: anthracycline/cyclophosphamide. MEC: Moderately emetogenic chemotherapy; HEC: Highly emetogenic chemotherapy. NSCLC: Non-small cell lung cancer. * In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration. A Balanced Portf

  5. Slide 5: Tim Pearson, Chief Financial Officer

    Tim Pearson Chief Financial Officer

  6. Slide 6: Q3 2014 Financial Results

    Q3 2014 Financial Results Three Months Ended September 30, 2014 Three Months Ended September 30, 2013 Expenses: Research & Development $29,925 $22,163 General & Administrative 6,263 4,503 Acquired In-process R&D -- 1,940 Total Expenses 36,188 28,606 Loss from Operations (36,188) (28,606) Interest In

  7. Slide 7: Mary Lynne Hedley, Ph.D., President and COO

    Mary Lynne Hedley, Ph.D. President and COO

  8. Slide 8: Development Programs Update

    Development Programs Update Oral rolapitant NDA accepted for review by FDA; anticipate standard 10 month review from date of filing Additional Phase 3 data presented at 2014 ESMO Congress A clinical trial has been initiated to compare the exposure of IV rolapitant to oral rolapitant Rolapitant Phase

  9. Slide 9: Development Programs Update

    Development Programs Update Oral rolapitant NDA accepted for review by FDA; anticipate standard 10 month review from the date of filing Additional Phase 3 data presented at 2014 ESMO Congress A clinical trial has been initiated to compare the exposure of IV rolapitant to oral rolapitant Rolapitant P

  10. Slide 10: Development Programs Update

    NDA: New drug application IV: Intravenous SCLC: Small cell lung cancer ESMO: European Society of Medical Oncology Development Programs Update Oral rolapitant NDA accepted for review by FDA; anticipate standard 10 month review from date of filing Additional Phase 3 data presented at 2014 ESMO Congres

  11. Slide 11: Development Programs Update

    Development Programs Update Oral rolapitant NDA accepted for review by FDA; anticipate standard 10 month review from date of filing Additional Phase 3 data presented at 2014 ESMO Congress A clinical trial has been initiated to compare the exposure of IV rolapitant to oral rolapitant Rolapitant Phase

  12. Slide 12: Lonnie Moulder, Chief Executive Officer

    Lonnie Moulder Chief Executive Officer

  13. Slide 13: Upcoming milestones and goals

    Advance the rolapitant IV bioequivalence program; Finish enrollment of the non-gBRCA cohort within the Phase 3 NOVA trial of niraparib at the end of 2014; Continue to enroll the Phase 3 BRAVO trial of niraparib in breast cancer patients; Identify a biomarker strategy to maximize the niraparib opport

  14. Slide 14: Q&A

    Q&A W TESARO

  15. Slide 15: Third-Quarter 2014 Results

    Third-Quarter 2014 Results November 5, 2014

TESARO — Q3 2014 Earnings Presentation on 6ix